Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964609 · ClinicalTrials.gov registry record · NA
EmbracePlus SpO2 Accuracy Validation
A NA study, sponsored by Empatica.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT04964609 is a NA study that has completed, run by Empatica. The registered enrollment target is 14 participants.
The verdict
NCT04964609, a NA study, has completed, sponsored by Empatica.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The aim of this study is to test the accuracy of EmbracePlus computed SpO2 during mild, moderate and severe hypoxia (a lower-than-normal concentration of oxygen in arterial blood); ie, a range of arterial HbO2 saturations from 100 to down to 70%. This is done by comparing the reading of the the subject device during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin (hemoglobin carrying oxygen) saturation, that is arterial blood sample processed in a laboratory.
Interventions
- DEVICE EmbracePlus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2022-11-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964609
The ClinicalTrials.gov registry entry for NCT04964609 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Empatica, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EmbracePlus is the first listed.
NCT04964609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04964609 about?
NCT04964609 is a clinical study titled "EmbracePlus SpO2 Accuracy Validation". The aim of this study is to test the accuracy of EmbracePlus computed SpO2 during mild, moderate and severe hypoxia (a lower-than-normal concentration of oxygen in arterial blood); ie, a range of arterial HbO2 saturations from 100 to down to 70%. This is done by comparing the reading of the the subj...
What is the current status of trial NCT04964609?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2021-06-16. Estimated completion is 2022-11-21.
What interventions are being tested in trial NCT04964609?
The interventions under investigation include: EmbracePlus (DEVICE).
Who is sponsoring clinical trial NCT04964609?
This trial is sponsored by Empatica, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.